Path: mechanisms/stress-granules-neurodegeneration Title: Stress Granules in Neurodegeneration Tags: section:mechanisms, kind:pathology, topic:rna-metabolism, topic:protein-aggregation, topic:als, topic:ftd
Stress granules (SGs) are membrane-less organelles that form in the cytoplasm of eukaryotic cells in response to various forms of cellular stress, including oxidative stress, heat shock, viral infection, and endoplasmic reticulum stress[@stress2016]. These dynamic assemblies function as temporary storage sites for translationally arrested mRNA and associated proteins, serving as a protective mechanism that allows cells to conserve resources and prioritize stress response pathways during challenging conditions[@stress2020]. The formation of stress granules represents a fundamental cellular response that is conserved across species, highlighting its essential role in cellular homeostasis.
Path: mechanisms/stress-granules-neurodegeneration Title: Stress Granules in Neurodegeneration Tags: section:mechanisms, kind:pathology, topic:rna-metabolism, topic:protein-aggregation, topic:als, topic:ftd
Stress granules (SGs) are membrane-less organelles that form in the cytoplasm of eukaryotic cells in response to various forms of cellular stress, including oxidative stress, heat shock, viral infection, and endoplasmic reticulum stress[@stress2016]. These dynamic assemblies function as temporary storage sites for translationally arrested mRNA and associated proteins, serving as a protective mechanism that allows cells to conserve resources and prioritize stress response pathways during challenging conditions[@stress2020]. The formation of stress granules represents a fundamental cellular response that is conserved across species, highlighting its essential role in cellular homeostasis.
In the context of neurodegenerative diseases, stress granules have emerged as critical pathological entities that connect RNA metabolism dysfunction to protein aggregation and neuronal death[@stress2019]. Numerous studies have demonstrated that mutations in genes encoding stress granule components cause familial forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), directly implicating SG dysfunction in disease pathogenesis[@als2020]. The identification of TDP-43, FUS, and [C9orf72](/entities/c9orf72) dipeptide repeat proteins as major components of disease-specific inclusions has solidified the link between stress granule biology and neurodegeneration[@tdp2018].
The significance of stress granules in neurodegenerative disease extends beyond their role as pathological inclusions. Dysregulated stress granule dynamics contribute to broader cellular dysfunction through multiple mechanisms, including impaired stress response signaling, disrupted RNA metabolism, altered protein homeostasis, and propagation of toxic species throughout the nervous system[@stress2016a]. Understanding the molecular mechanisms that regulate stress granule formation, composition, and disassembly provides crucial insights into disease pathogenesis and identifies potential therapeutic targets for intervention[@therapeutic2021].
| Component | Role | Disease Relevance |
|-----------|------|-------------------|
| G3BP1/2 | Core nucleation factor | ALS mutations |
| TIA-1 | Translation repression | ALS mutations |
| TDP-43 | RNA binding protein | 95% of ALS cases |
| FUS | RNA binding protein | 5-10% of ALS cases |
| C9orf72 DPRs | Toxic repeat proteins | Most common genetic cause |
Stress granules form through the process of liquid-liquid phase separation (LLPS), a physicochemical phenomenon whereby proteins and RNA coalesce into dense liquid-like assemblies that are distinct from the surrounding cytoplasm[@phase2017]. The driving forces for phase separation include multivalent interactions between proteins and RNA, the prion-like behavior of certain domain architectures, and the saturation of RNA-binding capacity that leads to condensation[@principles2018]. The resulting assemblies display properties of liquid droplets, including spherical morphology, fusion behavior, and dynamic internal rearrangements[@liquid2015].
The phase separation behavior of stress granule proteins is mediated by intrinsically disordered regions (IDRs) or prion-like domains that undergo concentration-dependent transitions from soluble to condensed states[@intrinsically2019]. These low-complexity sequences lack defined tertiary structure but facilitate cooperative interactions that drive condensate formation[@lowcomplexity2020]. The FG-Nucleoporin-like interactions and aromatic residue stacking in these domains provide the multivalency necessary for phase separation, while phosphorylation and other post-translational modifications regulate the transition between states[@posttranslational2019].
The material properties of stress granules exist on a continuum between liquid-like and gel-like or solid-like states, with important implications for their function and pathology[@material2020]. Under physiological conditions, stress granules maintain dynamic exchange of components with the surrounding cytoplasm, enabling rapid assembly and disassembly in response to changing cellular conditions[@dynamic2020]. Pathological transitions to more solid-like states can impair granule dynamics and contribute to the formation of irreversible aggregates that characterize neurodegenerative disease[@pathological2020]. The regulation of phase behavior through post-translational modifications and interactions with specific partners provides opportunities for therapeutic modulation[@modulating2018].
The integrated stress response (ISR) plays a central role in regulating stress granule formation through phosphorylation of the translation initiation factor eIF2α[@integrated2019]. Phosphorylated eIF2α (eIF2α-P) inhibits the eIF2-GTP-Met-tRNAi complex, blocking translation initiation and leading to the accumulation of stalled translation initiation complexes that nucleate stress granule formation[@eif2003]. The ISR is activated by distinct stress sensors that detect different forms of cellular perturbation, including PERK (ER stress), GCN2 (amino acid deprivation and ribosome stalling), PKR (viral infection), and HRI (heme deprivation and oxidative stress)[@stress2020a].
Beyond eIF2α phosphorylation, multiple signaling pathways modulate stress granule dynamics through effects on protein post-translational modifications, recruitment of specific components, and regulation of assembly factors[@signaling2021]. The mammalian target of rapamycin (mTOR) pathway negatively regulates SG formation by promoting translation, and [mTOR](/mechanisms/mtor-signaling-pathway) inhibition leads to SG assembly through both eIF2α-dependent and independent mechanisms[@mtor2013]. p38 mitogen-activated protein kinase signaling contributes to SG formation through phosphorylation of specific SG components, while AMPK activation promotes SG assembly as part of the cellular energy stress response[@p2020].
The temporal dynamics of stress granule formation and disassembly are tightly regulated to ensure appropriate cellular responses to stress[@temporal2020]. Following stress removal, stress granules disassemble through processes that involve the resumption of translation, changes in post-translational modifications, and active remodeling by cellular clearance mechanisms[@stress2018]. The kinetic parameters of SG assembly and disassembly are altered in disease states, with mutations in SG components causing either excessive or deficient granule formation that disrupts cellular homeostasis[@diseaseassociated2022]. Understanding these regulatory mechanisms provides insights into disease pathogenesis and identifies potential therapeutic targets[@therapeutic2015].
Stress granule dysfunction represents a central pathogenic mechanism in amyotrophic lateral sclerosis, with multiple lines of evidence linking SG abnormalities to motor neuron degeneration[@stress2022]. The identification of mutations in TDP-43, FUS, TIA1, andhnRNPA1 as causes of familial ALS confirms that perturbation of SG biology is sufficient to cause disease[@als2017]. These mutations alter SG dynamics through diverse mechanisms including enhanced recruitment to granules, increased aggregation propensity, impaired disassembly, and disrupted nucleocytoplasmic transport[@mutation2022].
TDP-43 pathology characterizes approximately 95% of ALS cases and the majority of FTD cases, representing the most common proteinopathy in these diseases[@tdp2006]. The transition of TDP-43 from dynamic SG-associated protein to insoluble aggregates represents a key disease mechanism that disconnects RNA metabolism from cellular stress responses[@tdp2020]. Pathological TDP-43 inclusions contain SG components including G3BP1 and TIA-1, indicating that SG dysfunction contributes to the formation of these disease-defining aggregates[@tdp2021]. The seeding of pathological TDP-43 aggregation through SG intermediates provides a mechanistic link between physiological stress responses and irreversible protein deposition[@seeding2020].
FUS pathology occurs in approximately 5-10% of ALS cases and is associated with aggressive disease progression and younger age of onset[@fus2017]. FUS mutations cause enhanced recruitment to stress granules and impaired granule dynamics, leading to the formation of pathological inclusions that sequester additional SG components[@fus2022]. The interactions between FUS pathology and other disease mechanisms, including nucleocytoplasmic transport defects and RNA metabolism dysfunction, create multiple points of vulnerability in affected [neurons](/entities/neurons)[@fus2021]. The presence of FUS in stress granules under physiological conditions and its recruitment to pathological inclusions in disease highlights the importance of SG biology in understanding ALS pathogenesis[@fus2014].
Frontotemporal dementia encompasses a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal brain regions, with clinical presentations that include behavioral variant FTD, semantic variant primary progressive aphasia, and nonfluent/agrammatic variant PPA[@ftd2011]. The overlap between FTD and ALS at the genetic, pathological, and clinical levels has established stress granule dysfunction as a shared disease mechanism[@ftd2009]. Mutations in C9orf72, GRN, VCP, and TARDBP cause both familial FTD and ALS, confirming the mechanistic link between SG biology and these diseases[@genetics2018].
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of both FTD and ALS, accounting for approximately 25% of familial cases of both conditions[@corf2017a]. The repeat expansion generates toxic dipeptide repeat proteins that localize to stress granules and disrupt their normal dynamics[@dpr2016]. Arginine-containing DPRs (poly-GR, poly-PR) are particularly potent disruptors of SG function, impairing nucleocytoplasmic transport, altering RNA metabolism, and promoting the recruitment of additional proteins to pathological inclusions[@arginine2017]. The sequestration of SG components and transport factors into C9orf72 DPR-containing granules provides a mechanism for the widespread cellular dysfunction observed in affected individuals[@corf2022].
GRN (progranulin) mutations cause approximately 10-20% of familial FTD cases through haploinsufficiency mechanisms that reduce progranulin protein levels[@progranulin2006]. Progranulin localizes to stress granules and regulates their dynamics through interactions with protein partners that remain incompletely characterized[@progranulin2019]. Loss of progranulin function leads to altered SG responses to stress, with implications for RNA metabolism and protein homeostasis in affected neurons[@progranulin2018]. The connection between progranulin and stress granule biology provides additional evidence for the importance of SG dysfunction in FTD pathogenesis[@grn2022].
While stress granules are most strongly associated with ALS and FTD, evidence increasingly supports their involvement in other neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease[@stress2012]. In Alzheimer's disease, stress granule components including TDP-43 and G3BP1 are found in association with [tau](/proteins/tau) pathology, and SG-like structures are observed in affected brain regions[@tdp2014]. The integrated stress response is activated in Alzheimer's disease, and eIF2α phosphorylation contributes to the translation deficits that characterize the disease[@isr2021].
In Parkinson's disease, stress granule formation occurs in response to [alpha-synuclein](/proteins/alpha-synuclein) toxicity and mitochondrial stress, with SG components accumulating in disease-specific inclusions[@stress2021]. The relationship between alpha-synuclein pathology and stress granule biology involves both direct interactions between proteins and indirect effects through cellular stress pathways[@alphasynuclein2022]. Mutations in genes linked to familial Parkinson's disease, including LRRK2 and GBA, alter stress granule dynamics, suggesting that SG dysfunction may contribute to disease pathogenesis[@lrrk2020].
Huntington's disease shows evidence of stress granule involvement through the recruitment of various SG components to mutant [huntingtin](/proteins/huntingtin) inclusions[@huntingtons2001]. The expansion of the huntingtin polyglutamine tract alters protein interactions and cellular stress responses in ways that affect SG dynamics[@mutant2019]. The connections between SG biology and multiple neurodegenerative conditions suggest that understanding stress granule dysfunction may provide broadly applicable therapeutic insights[@dysfunction2015].
The central role of stress granule dysfunction in neurodegenerative disease makes SG biology an attractive target for therapeutic intervention[@targeting2019]. Strategies to modulate stress granule dynamics include approaches to prevent pathological transition from dynamic granules to static aggregates, enhance granule disassembly, and restore normal SG function[@modulating2021]. Small molecules that promote SG disassembly or prevent their formation are being explored for potential disease modification in ALS and FTD[@small2020].
The regulation of stress granule dynamics through post-translational modifications provides opportunities for pharmacological intervention[@kinase2021]. Kinase inhibitors that reduce eIF2α phosphorylation could decrease excessive SG formation, while phosphatase activators could promote granule disassembly[@eif2018]. The development of compounds that specifically target SG-associated proteins, including TDP-43 and FUS, offers the potential for disease-specific interventions[@tdp2022]. Understanding the molecular determinants of pathological SG transitions will be essential for developing effective therapeutics[@molecular2020].
The fundamental role of phase separation in stress granule formation suggests that targeting LLPS dynamics may provide therapeutic benefits[@phase2019]. Small molecules that modulate the phase behavior of proteins with prion-like domains could prevent the transition to pathological aggregates while preserving normal SG function[@modulating2018a]. The identification of compounds that specifically dissolve pathological aggregates without affecting physiological SG assembly represents a significant challenge but also a promising therapeutic approach[@dissolving2019].
The material properties of stress granules, including their viscosity and dynamics, can be modulated through changes in protein post-translational modifications or interactions with specific partners[@material2018]. Targeting these regulatory mechanisms offers opportunities to shift the balance toward more dynamic, liquid-like SG states that are less likely to transition to pathological aggregates[@shifting2016]. The development of biomarkers that reflect SG dynamics could enable patient stratification and treatment response monitoring for emerging therapies[@biomarkers2021].
Recent advances in stress granules and neurodegeneration: